125 related articles for article (PubMed ID: 16723171)
41. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
42. Does gefitinib shorten lung cancer survival? Chaos redux.
Keedy VL; Arteaga CL; Johnson DH
J Clin Oncol; 2008 May; 26(15):2428-30. PubMed ID: 18378565
[No Abstract] [Full Text] [Related]
43. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
44. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Liu G; Gurubhagavatula S; Zhou W; Wang Z; Yeap BY; Asomaning K; Su L; Heist R; Lynch TJ; Christiani DC
Pharmacogenomics J; 2008 Apr; 8(2):129-38. PubMed ID: 17375033
[TBL] [Abstract][Full Text] [Related]
45. Gefitinib (IRESSA, ZD 1839) as a salvage treatment for patients with advanced non-small cell lung cancer.
Jubelirer SJ; Yadwadkar KS; Kosowicz AB
W V Med J; 2006; 102(6):14-7. PubMed ID: 17334161
[TBL] [Abstract][Full Text] [Related]
46. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.
Simon GR; Ruckdeschel JC; Williams C; Cantor A; Chiappori A; Rocha Lima CM; Antonia S; Haura E; Wagner H; Robinson L; Sommers E; Alberts M; Bepler G
Cancer Control; 2003; 10(5):388-95. PubMed ID: 14581894
[TBL] [Abstract][Full Text] [Related]
47. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
Damyanov D; Koynov K; Naseva E; Bichev S
J BUON; 2015; 20(1):136-41. PubMed ID: 25778308
[TBL] [Abstract][Full Text] [Related]
48. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
[No Abstract] [Full Text] [Related]
49. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
50. Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan.
Yang CT; Hung JY; Lai CL; Hung HC; Lai YF; Lin MC; Shieh JM; Huang MS
Kaohsiung J Med Sci; 2010 Jan; 26(1):1-7. PubMed ID: 20040466
[TBL] [Abstract][Full Text] [Related]
51. Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
Sharma A; Tan TH; Cheetham G; Scott HS; Brown MP
J Thorac Oncol; 2012 May; 7(5):941-2. PubMed ID: 22722798
[No Abstract] [Full Text] [Related]
52. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
53. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
[TBL] [Abstract][Full Text] [Related]
54. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
[TBL] [Abstract][Full Text] [Related]
55. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
56. Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib.
Chen MJ; Zhong W; Zhang L; Zhao J; Li LY; Wang MZ
Chin Med J (Engl); 2013 Jun; 126(12):2235-41. PubMed ID: 23786931
[TBL] [Abstract][Full Text] [Related]
57. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Hotta K; Ueoka H; Kiura K; Tabata M; Ogino A; Umemura S; Harita S; Gemba K; Yonei T; Bessho A; Maeda T; Tanimoto M
Acta Oncol; 2005; 44(7):717-22. PubMed ID: 16227162
[TBL] [Abstract][Full Text] [Related]
59. [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].
Wang B; Zhang XR; Chu DT
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):549-51. PubMed ID: 18069641
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]